GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Press Release

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients 2023-12-11

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients   Ventegra® will list VEGZELMA®(bevacizumab-adcd) on its national formulary that serves more than 400 clients and more than 13 million members and patients in the U.S. Celltrion USA completes a contract ...

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs 2023-10-26

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May ...

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease 2023-10-23

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of i...

게시물 검색
  • 65
    Celltrion Healthcare receives EU CHMP positive opi..
    Celltrion Healthcare receives EU CHMP positive opinion for biosimilar adalimumab, CT-P17 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of CT-P17 (adalimum…
    2020-12-11
  • 64
    Celltrion completes enrolment for global Phase II ..
    Celltrion completes enrolment for global Phase II clinical trial with COVID-19 treatment candidate CT-P59 Celltrion announced enrolment completion of 327 COVID-19 patients in the global Phase II clinical trial The trial is designed to…
    2020-11-25
  • 63
    Celltrion presents efficacy and safety data for po..
    Celltrion presents efficacy and safety data for potential COVID-19 treatment candidate CT-P59 in patients with mild symptoms Trial results indicate treatment with CT-P59 resulted in at least 44% faster recovery time when compared with p…
    2020-11-06
  • 62
    Celltrion Healthcare Presents Positive Top-Line Ef..
    Celltrion Healthcare Presents Positive Top-Line Efficacy and Safety Results for CT-P17 in the Treatment of Rheumatoid Arthritis CT-P17 is the first biosimilar with high concentration (100mg/mL) and citrate-free formulation 24-week dat…
    2020-11-03
  • 61
    Celltrion Initiates Post-exposure Prophylaxis Clin..
    Celltrion Initiates Post-exposure Prophylaxis Clinical Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59 The Korean Ministry of Food and Drug Safety (MFDS) has approved Celltrion’s Investigational New Drug (IND) applica…
    2020-10-12
  • 60
    New data presented at UEG Week Virtual 2020 show p..
    New data presented at UEG Week Virtual 2020 show positive association between Remsima® SC pre-dose level with efficacy outcomes Data show positive association between subcutaneous infliximab (Remsima®SC / CT-P13 SC) exposure with efficacy and …
    2020-10-10
  • 59
    Celltrion receives Korean MFDS approval to initiat..
    Celltrion receives Korean MFDS approval to initiate Phase II/III pivotal trial of an anti-COVID-19 monoclonal antibody treatment candidate, CT-P59 ● Following positive interim results of the Phase I clinical trial of CT-P591, the Korean Minis…
    2020-09-17
  • 58
    Celltrion Announces Positive Interim Results From ..
    Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59, an Anti-COVID-19 Monoclonal Antibody Treatment Candidate CT-P59 demonstrated a reassuring safety profile in Celltrion’s Phase I trial The company anticipates enrolmen…
    2020-09-11
  • 57
    Celltrion receives Korean MFDS approval to initiat..
    Celltrion receives Korean MFDS approval to initiate Phase I trial of COVID-19 antiviral antibody treatment candidate, CT-P59, in patients The Korean Ministry of Food and Drug Safety (MFDS) approved Celltrion’s Investigational New Drug (IND) ap…
    2020-08-26
  • 56
    Celltrion receives MHRA approval to initiate Phase..
    Celltrion receives MHRA approval to initiate Phase I trial of potential COVID-19 antiviral antibody treatment, CT-P59, in the UK The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Celltrion’s clinical trial au…
    2020-07-30